


PHARMACEUTICAL 2019

PUMA BIOTECHNOLOGY INC. Rank 194 of 371









PHARMACEUTICAL 2019

PUMA BIOTECHNOLOGY INC. Rank 194 of 371



The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 309% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is -175%, being 156% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	203,003
Cost of Goods Sold	34,621
Intangible Assets	0
Liabilities, Current	67,115
Liabilities, Non-Current	0
Other Assets	52,156
Other Compr. Net Income	-12
Other Expenses	0
Other Liabilities	157,701
Other Net Income	-18,903
Property and Equipment	3,963
Research and Development	164,854
Revenues	250,991
Selling, General and Administrative Expense	146,188

Output Variable	Value in 1000 USD
Assets	259,122
Liabilities	224,816
Expenses	345,663
Stockholders Equity	34,306
Net Income	-113,575
Comprehensive Net Income	-113,581
Economic Capital Ratio	-175%

